Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Small Pharma Announces Additional Positive Data From Phase 2a Trial
Patients and investors received additional good news, as Small Pharma has reported supportive data to corroborate its initial Phase 2 trial topline results.
“Analyses of additional secondary and exploratory endpoints, including effects on self-reported depression, anxiety and wellbeing, demonstrated that patients receiving at least a single dose of IV SPL026 with supportive therapy experienced clinically relevant improvements in function and mood, further supporting previously announced topline efficacy results.”
Cybin Presents New Data on CYB-003 Trial R&D day
Last year, Cybin launched the Phase 1 portion of a Phase 1/2a clinical study, testing the safety and tolerability of CYB003. This part has now been completed, and the initial data was presented at their R&D day. Ever since CYB003 was first announced, Cybin has touted three core differences between the next-gen psilocybin and the original. Using animal data, Cybin claimed that CYB003:
- Is shorter-acting and has a faster onset than psilocybin
- Causes less variation in plasma levels between different individuals taking it — meaning that the effects would be more consistent across different people
- Can be administered at lower dose levels with the same effect
GH Research Expands Access to Capital With $200 M Offering
GH Research prepares to potentially add to its already fat bank account, as it files for a mixed shelf of up to $200 million.
The company’s cash reserves and marketable securities were $251.7 million as of December 31, 2022.
Missouri Lawmakers Approve Bill To Promote Research On Psychedelics’ Medical Benefits
Missouri lawmakers have approved a GOP-led bill in committee to promote research into the therapeutic potential of certain psychedelics such as psilocybin, MDMA and ketamine. See this update from Marijuana Moment.
A Deeper Look at MindMed’s Company Update
On March 8th, MindMed CEO Robert Barrow spoke for 30 minutes at the 43rd annual Cowen Healthcare Conference. During his online appearance, Barrow walked through the psychedelic pharma company’s latest investor presentation, and gave details and insight into each of MindMed’s projects.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
